1
|
Tracy W, Davies GHM, Grant LN, Ganley JM, Moreno J, Cherney EC, Davies HML. Anhydrous and Stereoretentive Fluoride-Enhanced Suzuki-Miyaura Coupling of Immunomodulatory Imide Drug Derivatives. J Org Chem 2024; 89:4595-4606. [PMID: 38452367 PMCID: PMC11002932 DOI: 10.1021/acs.joc.3c02873] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2023] [Revised: 02/12/2024] [Accepted: 02/17/2024] [Indexed: 03/09/2024]
Abstract
Immunomodulatory imide drugs form the core of many pharmaceutically relevant structures, but Csp2-Csp2 bond formation via metal-catalyzed cross coupling is difficult due to the sensitivity of the glutarimide ring ubiquitous in these structures. We report that replacement of the traditional alkali base with a fluoride source enhances a previously challenging Suzuki-Miyaura coupling on glutarimide-containing compounds with trifluoroborates. These enabling conditions are reactive enough to generate these derivatives in high yields but mild enough to preserve both the glutarimide and its sensitive stereocenter. Experimental and computational data suggest a mechanistically distinct process of π-coordination of the trifluoroborate enabled by these conditions.
Collapse
Affiliation(s)
- William
F. Tracy
- Department
of Chemistry, Emory University, Atlanta, Georgia 30322, United States
| | - Geraint H. M. Davies
- Small
Molecule Drug Discovery, Bristol Myers Squibb, Cambridge, Massachusetts 02140, United States
| | - Lauren N. Grant
- Chemical
Process Development, Bristol Myers Squibb, New Brunswick, New Jersey 08903, United States
| | - Jacob M. Ganley
- Chemical
Process Development, Bristol Myers Squibb, New Brunswick, New Jersey 08903, United States
| | - Jesus Moreno
- Small
Molecule Drug Discovery, Bristol Myers Squibb, San Diego, California 92121, United States
| | - Emily C. Cherney
- Small
Molecule Drug Discovery, Bristol Myers Squibb, Princeton, New Jersey 08543, United States
| | - Huw M. L. Davies
- Department
of Chemistry, Emory University, Atlanta, Georgia 30322, United States
| |
Collapse
|
2
|
Nayek U, Basheer Ahamed SI, Mansoor Hussain UH, Unnikrishnan MK, Abdul Salam AA. Computational investigations of indanedione and indanone derivatives in drug discovery: Indanone derivatives inhibits cereblon, an E3 ubiquitin ligase component. Comput Biol Chem 2022; 101:107776. [PMID: 36252444 DOI: 10.1016/j.compbiolchem.2022.107776] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2022] [Revised: 09/30/2022] [Accepted: 10/05/2022] [Indexed: 11/25/2022]
Abstract
BACKGROUND Cereblon, an extensively studied multifunctional protein, is a Cullin 4-RING E3 ubiquitin ligase complex component. Cereblon is a well-known target of thalidomide and its derivatives. Cereblon is involved in multiple myeloma cell apoptosis. When ligands such as thalidomide and lenalidomide bind to cereblon, it recognizes various neosubstrates based on the ligand shape and properties. We have identified novel CRBN inhibitors, namely DHFO and its analogs, with structural features that are slightly different from thalidomide but stronger cereblon-binding affinity. We selected indanedione and indanone derivatives from the literature to understand and compare their cereblon-mediated substrate recognition potential. METHODS Computational investigations of possible CRBN inhibitors were investigated by molecular docking with Autodock Vina and DockThor programs. The properties of the compounds' ADME/T and drug-likeness were investigated. A molecular dynamics study was carried out for four selected molecules, and the molecular interactions were analyzed using PCA-based FEL methods. The binding affinity was calculated using the MM/PBSA method. RESULTS We conducted computational investigations on 68 indanedione and indanone derivatives binding with cereblon. Ten molecules showed better CRBN binding affinity than thalidomide. We studied the drug-likeness properties of the selected ten molecules, and four of the most promising molecules (DHFO, THOH, DIMS, and DTIN) were chosen for molecular dynamics studies. The MM/PBSA calculations showed that the DHFO, already shown to be a 5-LOX/COX2 inhibitor, has the highest binding affinity of - 163.16 kJ/mol with cereblon. CONCLUSION The selected CRBN inhibitor DHFO has demonstrated the highest binding affinity with cereblon protein compared to other molecules. Thalidomide and its derivatives have a new substitute in the form of DHFO, which produces an interaction hotspot on the surface of the cereblon. Ease of chemical synthesis, low toxicity, versatile therapeutic options, and pleiotropism of DHFO analogs provide an opportunity for exploring clinical alternatives with versatile therapeutic potential for a new category of indanedione molecules as novel modulators of E3 ubiquitin ligases.
Collapse
|
3
|
Sosič I, Bricelj A, Steinebach C. E3 ligase ligand chemistries: from building blocks to protein degraders. Chem Soc Rev 2022; 51:3487-3534. [PMID: 35393989 DOI: 10.1039/d2cs00148a] [Citation(s) in RCA: 51] [Impact Index Per Article: 25.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
In recent years, proteolysis-targeting chimeras (PROTACs), capable of achieving targeted protein degradation, have proven their great therapeutic potential and usefulness as molecular biology tools. These heterobifunctional compounds are comprised of a protein-targeting ligand, an appropriate linker, and a ligand binding to the E3 ligase of choice. A successful PROTAC induces the formation of a ternary complex, leading to the E3 ligase-mediated ubiquitination of the targeted protein and its proteasomal degradation. In over 20 years since the concept was first demonstrated, the field has grown substantially, mainly due to the advancements in the discovery of non-peptidic E3 ligase ligands. Development of small-molecule E3 binders with favourable physicochemical profiles aided the design of PROTACs, which are known for breaking the rules of established guidelines for discovering small molecules. Synthetic accessibility of the ligands and numerous successful applications led to the prevalent use of cereblon and von Hippel-Lindau as the hijacked E3 ligase. However, the pool of over 600 human E3 ligases is full of untapped potential, which is why expanding the artillery of E3 ligands could contribute to broadening the scope of targeted protein degradation. In this comprehensive review, we focus on the chemistry aspect of the PROTAC design process by providing an overview of liganded E3 ligases, their chemistries, appropriate derivatisation, and synthetic approaches towards their incorporation into heterobifunctional degraders. By covering syntheses of both established and underexploited E3 ligases, this review can serve as a chemistry blueprint for PROTAC researchers during their future ventures into the complex field of targeted protein degradation.
Collapse
Affiliation(s)
- Izidor Sosič
- Faculty of Pharmacy, University of Ljubljana, SI-1000 Ljubljana, Slovenia
| | - Aleša Bricelj
- Faculty of Pharmacy, University of Ljubljana, SI-1000 Ljubljana, Slovenia
| | - Christian Steinebach
- Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany
| |
Collapse
|
4
|
Bricelj A, Steinebach C, Kuchta R, Gütschow M, Sosič I. E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points. Front Chem 2021; 9:707317. [PMID: 34291038 PMCID: PMC8287636 DOI: 10.3389/fchem.2021.707317] [Citation(s) in RCA: 92] [Impact Index Per Article: 30.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2021] [Accepted: 06/04/2021] [Indexed: 12/16/2022] Open
Abstract
Proteolysis-targeting chimeras (PROTACs) have received tremendous attention as a new and exciting class of therapeutic agents that promise to significantly impact drug discovery. These bifunctional molecules consist of a target binding unit, a linker, and an E3 ligase binding moiety. The chemically-induced formation of ternary complexes leads to ubiquitination and proteasomal degradation of target proteins. Among the plethora of E3 ligases, only a few have been utilized for the novel PROTAC technology. However, extensive knowledge on the preparation of E3 ligands and their utilization for PROTACs has already been acquired. This review provides an in-depth analysis of synthetic entries to functionalized ligands for the most relevant E3 ligase ligands, i.e. CRBN, VHL, IAP, and MDM2. Less commonly used E3 ligase and their ligands are also presented. We compare different preparative routes to E3 ligands with respect to feasibility and productivity. A particular focus was set on the chemistry of the linker attachment by discussing the synthetic opportunities to connect the E3 ligand at an appropriate exit vector with a linker to assemble the final PROTAC. This comprehensive review includes many facets involved in the synthesis of such complex molecules and is expected to serve as a compendium to support future synthetic attempts towards PROTACs.
Collapse
Affiliation(s)
- Aleša Bricelj
- Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia
| | | | - Robert Kuchta
- Pharmaceutical Institute, University of Bonn, Bonn, Germany
| | | | - Izidor Sosič
- Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia
| |
Collapse
|
5
|
Nutt MJ, Yee YS, Buyan A, Andrewartha N, Corry B, Yeoh GCT, Stewart SG. In pursuit of a selective hepatocellular carcinoma therapeutic agent: Novel thalidomide derivatives with antiproliferative, antimigratory and STAT3 inhibitory properties. Eur J Med Chem 2021; 217:113353. [PMID: 33773263 DOI: 10.1016/j.ejmech.2021.113353] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2021] [Revised: 02/25/2021] [Accepted: 02/26/2021] [Indexed: 12/24/2022]
Abstract
Advanced stage liver cancer is predominantly treated with the multi-kinase inhibitor sorafenib; however, this therapeutic agent lacks selectivity in its cytotoxic actions and is associated with poor survival outcomes. Herein we report the design and preparation of several thalidomide derivatives, including a variety of novel thioether-containing forms that are especially rare in the literature. Importantly, two of the derivatives described are potent antiproliferative agents with dose-dependent selectivity for tumorigenic liver progenitor cells (LPC) growth inhibition (up to 36% increase in doubling time at 10 μM) over non-tumorigenic cells (no effect at 10 μM). Furthermore, these putative anti-liver cancer agents were also found to be potent inhibitors of tumorigenic LPC migration. This report also describes these derivatives' effects on several key signalling pathways in our novel liver cell lines by immunofluorescence and AlphaLISA assays. Aryl thioether derivative 7f significantly reduced STAT3 phosphorylation (23%) and its nuclear localisation (16%) at 10 μM in tumorigenic LPCs, implicating the IL-6/JAK/STAT3 axis is central in the mode of action of our derivatives.
Collapse
Affiliation(s)
- Michael J Nutt
- School of Molecular Sciences, The University of Western Australia, Crawley, WA, 6009, Australia; The Centre for Medical Research, The Perkins Institute of Medical Research, Nedlands, WA, 6009, Australia
| | - Yeung Sing Yee
- School of Molecular Sciences, The University of Western Australia, Crawley, WA, 6009, Australia
| | - Amanda Buyan
- Research School of Biology, Australian National University, Acton, ACT, 2601, Australia
| | - Neil Andrewartha
- School of Molecular Sciences, The University of Western Australia, Crawley, WA, 6009, Australia; The Centre for Medical Research, The Perkins Institute of Medical Research, Nedlands, WA, 6009, Australia
| | - Ben Corry
- Research School of Biology, Australian National University, Acton, ACT, 2601, Australia
| | - George C T Yeoh
- School of Molecular Sciences, The University of Western Australia, Crawley, WA, 6009, Australia; The Centre for Medical Research, The Perkins Institute of Medical Research, Nedlands, WA, 6009, Australia
| | - Scott G Stewart
- School of Molecular Sciences, The University of Western Australia, Crawley, WA, 6009, Australia.
| |
Collapse
|
6
|
Almeida ML, Oliveira MC, Pitta IR, Pitta MG. Advances in Synthesis and Medicinal Applications of Compounds Derived from Phthalimide. Curr Org Synth 2020; 17:252-270. [DOI: 10.2174/1570179417666200325124712] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2019] [Revised: 02/20/2020] [Accepted: 02/21/2020] [Indexed: 12/20/2022]
Abstract
Phthalimide derivatives have been presenting several promising biological activities in the literature,
such as anti-inflammatory, analgesic, antitumor, antimicrobial and anticonvulsant. The most well-known and
studied phthalimide derivative (isoindoline-1,3-dione) is thalidomide: this compound initially presented
important sedative effects, but it is now known that thalidomide has effectiveness against a wide variety of
diseases, including inflammation and cancer. This review approaches some of the recent and efficient chemical
synthesis pathways to obtain phthalimide analogues and also presents a summary of the main biological
activities of these derivatives found in the literature. Therefore, this review describes the chemical and
therapeutic aspects of phthalimide derivatives.
Collapse
Affiliation(s)
- Marcel L. Almeida
- Nucleus of Research in Therapeutical Innovation Suely Galdino (NUPIT SG), Bioscience Center, Federal University of Pernambuco, Recife, Brazil
| | - Maria C.V.A. Oliveira
- Nucleus of Research in Therapeutical Innovation Suely Galdino (NUPIT SG), Bioscience Center, Federal University of Pernambuco, Recife, Brazil
| | - Ivan R. Pitta
- Nucleus of Research in Therapeutical Innovation Suely Galdino (NUPIT SG), Bioscience Center, Federal University of Pernambuco, Recife, Brazil
| | - Marina G.R. Pitta
- Nucleus of Research in Therapeutical Innovation Suely Galdino (NUPIT SG), Bioscience Center, Federal University of Pernambuco, Recife, Brazil
| |
Collapse
|
7
|
Xiao D, Wang YJ, Wang HL, Zhou YB, Li J, Lu W, Jin J. Design and synthesis of new lenalidomide analogs via Suzuki cross-coupling reaction. Arch Pharm (Weinheim) 2020; 353:e1900376. [PMID: 32342558 DOI: 10.1002/ardp.201900376] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2019] [Revised: 03/26/2020] [Accepted: 03/27/2020] [Indexed: 11/09/2022]
Abstract
Lenalidomide is a cereblon modulator known for its antitumor, anti-inflammatory, and immunomodulatory properties in clinical applications. Recently, some reported lenalidomide analogs could exhibit a significant bioactivity through various modifications in the isoindolinone ring. In this study, we designed and synthesized a series of novel lenalidomide analogs on the basis of the installation of a methylene chain at the C-4 position of isoindolinone via the Suzuki cross-coupling reaction. These new compounds were further evaluated for their in vitro antiproliferative activities against two tumor cell lines (MM.1S and Mino). Specifically, compound 4c displayed the strongest antiproliferative activity against the MM.1S (IC50 = 0.27 ± 0.03 μM) and Mino (IC50 = 5.65 ± 0.58 μM) tumor cell lines. In summary, we have developed a new synthetic strategy for C-4 derivatization of lenalidomide, providing a bioactive scaffold that could be used to discover further potential antitumor lead compounds in pharmaceutical research.
Collapse
Affiliation(s)
- Donghuai Xiao
- School of Chemistry and Molecular Engineering, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, East China Normal University, Shanghai, China
| | - Yu-Jie Wang
- State Key Laboratory of Drug Research, National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
| | - Han-Lin Wang
- State Key Laboratory of Drug Research, National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.,University of Chinese Academy of Sciences, Beijing, China.,School of Life Science and Technology, Shanghai Tech University, Shanghai, China
| | - Yu-Bo Zhou
- State Key Laboratory of Drug Research, National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
| | - Jia Li
- State Key Laboratory of Drug Research, National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.,University of Chinese Academy of Sciences, Beijing, China.,School of Life Science and Technology, Shanghai Tech University, Shanghai, China.,Pilot National Laboratory for Marine Science and Technology (Qingdao), Open Studio for Druggability Research of Marine Natural Products, Qingdao, China
| | - Wei Lu
- School of Chemistry and Molecular Engineering, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, East China Normal University, Shanghai, China
| | - Jiyu Jin
- School of Chemistry and Molecular Engineering, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, East China Normal University, Shanghai, China
| |
Collapse
|
8
|
Rani A, Viljoen A, Johansen MD, Kremer L, Kumar V. Synthesis, anti-mycobacterial and cytotoxic evaluation of substituted isoindoline-1,3-dione-4-aminoquinolines coupled via alkyl/amide linkers. RSC Adv 2019; 9:8515-8528. [PMID: 35518673 PMCID: PMC9061829 DOI: 10.1039/c8ra10532d] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2018] [Accepted: 03/03/2019] [Indexed: 01/19/2023] Open
Abstract
A series of secondary amine-substituted isoindoline-1,3-dione-4-aminoquinolines were prepared via microwave heating and assayed for their anti-mycobacterial activities. The compound with a butyl chain as a spacer between the two pharmacophores and piperidine as the secondary amine component on the isoindoline ring was the most potent and non-cytotoxic among the synthesized compounds, exhibiting a minimum inhibitory concentration (MIC99) of 6.25 μg mL−1 against Mycobacterium tuberculosis. A series of secondary amine-substituted isoindoline-1,3-dione-4-aminoquinolines were prepared via microwave heating and assayed for their anti-mycobacterial activities.![]()
Collapse
Affiliation(s)
- Anu Rani
- Department of Chemistry
- Guru Nanak Dev University
- Amritsar-143005
- India
| | - Albertus Viljoen
- Institut de Recherche en Infectiologie (IRIM) de Montpellier
- CNRS
- UMR 9004 Université de Montpellier
- France
| | - Matt D. Johansen
- Institut de Recherche en Infectiologie (IRIM) de Montpellier
- CNRS
- UMR 9004 Université de Montpellier
- France
| | - Laurent Kremer
- Institut de Recherche en Infectiologie (IRIM) de Montpellier
- CNRS
- UMR 9004 Université de Montpellier
- France
- INSERM
| | - Vipan Kumar
- Department of Chemistry
- Guru Nanak Dev University
- Amritsar-143005
- India
| |
Collapse
|
9
|
|
10
|
Rani A, Viljoen A, Sumanjit, Kremer L, Kumar V. Microwave-Assisted Highly Efficient Route to 4-Aminoquinoline-Phthalimide Conjugates: Synthesis and Anti-Tubercular Evaluation. ChemistrySelect 2017. [DOI: 10.1002/slct.201702220] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Anu Rani
- Department of Chemistry; Guru Nanak Dev University; Amritsar- 143005 India
| | - Albertus Viljoen
- Institut de Recherche en Infectiologie (IRIM); CNRS, UMR 9004; Université de Montpellier; France
| | - Sumanjit
- Department of Chemistry; Guru Nanak Dev University; Amritsar- 143005 India
| | - Laurent Kremer
- Institut de Recherche en Infectiologie (IRIM); CNRS, UMR 9004; Université de Montpellier; France
- INSERM, IRIM; 34293 Montpellier France
| | - Vipan Kumar
- Department of Chemistry; Guru Nanak Dev University; Amritsar- 143005 India
| |
Collapse
|
11
|
Kumar V, Chand K, Chorell E. Synthesis of Various N
-Substituted 4-Aryloxy/Thiophenoxy/Thioisopropyloxy-Phthalimides. ChemistrySelect 2017. [DOI: 10.1002/slct.201700721] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Affiliation(s)
- Vipan Kumar
- Department of Chemistry; Umeå University; Linnaeus väg 10 901 87 Umeå Sweden
- Department of Chemistry; Guru Nanak Dev University; Amritsar- 143005 India
| | - Karam Chand
- Department of Chemistry; Umeå University; Linnaeus väg 10 901 87 Umeå Sweden
| | - Erik Chorell
- Department of Chemistry; Umeå University; Linnaeus väg 10 901 87 Umeå Sweden
| |
Collapse
|
12
|
Godin AM, Araújo DP, Menezes RR, de Brito AMS, Melo ISF, Coura GME, Bastos LFS, Amaral FA, Teixeira MM, de Fátima Â, Coelho MM, Machado RR. 2-Phthalimidethanol and 2-phthalimidethyl nitrate inhibit mechanical allodynia, neutrophil recruitment and cytokine and chemokine production in a murine model of articular inflammation. Pharmacol Rep 2017; 69:691-695. [PMID: 28550800 DOI: 10.1016/j.pharep.2017.01.033] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2016] [Revised: 01/16/2017] [Accepted: 01/30/2017] [Indexed: 12/31/2022]
Abstract
BACKGROUND Phthalimide analogs have been shown to exhibit anti-inflammatory, analgesic and immunomodulatory activities in different preclinical assays. This study aimed to investigate the potential role of 2-phthalimidethanol (PTD-OH) and 2-phthalimidethyl nitrate (PTD-NO) in a murine model of antigen-induced articular inflammation. METHODS Articular inflammation was induced by intra-articular injection of methylated bovine serum albumin (mBSA) in the knee joint of immunized male C57BL/6J mice. The animals were pre-treated with PTD-OH or PTD-NO (500mg/kg, per os, - 1h). Nociceptive threshold was measured using an electronic von Frey apparatus. The total number of leukocytes in the synovial cavity was determined. Concentrations of tumor necrosis factor (TNF)-α and CXCL-1 and myeloperoxidase (MPO) activity were determined in periarticular tissue. RESULTS Both PTD-OH and PTD-NO inhibited at similar extent the mechanical allodynia, neutrophil recruitment to the synovial cavity and periarticular tissue and TNF-α and CXCL-1 production induced by intra-articular challenge with mBSA in immunized mice. CONCLUSIONS PTD-OH and PTD-NO exhibit a marked activity in a murine model of antigen-induced articular inflammation in immunized animals. These results reinforce the interest in the investigation of phthalimide analogs devoid of the glutarimide ring as candidates to analgesic and anti-inflammatory drugs.
Collapse
Affiliation(s)
- Adriana M Godin
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
| | - Débora P Araújo
- Departamento de Química, Instituto de Ciências Exatas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
| | - Raquel R Menezes
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
| | - Ana M S de Brito
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
| | - Ivo S F Melo
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
| | - Giovanna M E Coura
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
| | - Leandro F S Bastos
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
| | - Flávio A Amaral
- Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
| | - Mauro M Teixeira
- Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
| | - Ângelo de Fátima
- Departamento de Química, Instituto de Ciências Exatas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
| | - Márcio M Coelho
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
| | - Renes R Machado
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
| |
Collapse
|
13
|
Lohbeck J, Miller AK. Practical synthesis of a phthalimide-based Cereblon ligand to enable PROTAC development. Bioorg Med Chem Lett 2016; 26:5260-5262. [PMID: 27687673 DOI: 10.1016/j.bmcl.2016.09.048] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2016] [Revised: 09/16/2016] [Accepted: 09/17/2016] [Indexed: 11/29/2022]
Abstract
The use of small molecules to regulate cellular levels of specific proteins is poised to become a powerful technique in the coming years. Critical to the success of any project utilizing such an approach will be the ability to synthesize libraries of candidate small molecules for testing in cellular systems. Herein, we describe a practical synthesis of a phthalimide-based scaffold, which can be easily diversified to make Cereblon-targeting PROTACs. We demonstrate the effectiveness of this approach by synthesizing a 'PROTAC toolbox' of four amines which can be coupled to inhibitors in a straightforward manner.
Collapse
Affiliation(s)
- Jasmin Lohbeck
- Cancer Drug Development Group, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany
| | - Aubry K Miller
- Cancer Drug Development Group, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany.
| |
Collapse
|
14
|
Woo K, Stewart SG, Kong GS, Finch-Edmondson ML, Dwyer BJ, Yeung SY, Abraham LJ, Kampmann SS, Diepeveen LA, Passman AM, Elsegood CL, Tirnitz-Parker JEE, Callus BA, Olynyk JK, Yeoh GCT. Identification of a thalidomide derivative that selectively targets tumorigenic liver progenitor cells and comparing its effects with lenalidomide and sorafenib. Eur J Med Chem 2016; 120:275-83. [PMID: 27208658 DOI: 10.1016/j.ejmech.2016.03.015] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2015] [Revised: 02/18/2016] [Accepted: 03/04/2016] [Indexed: 01/01/2023]
Abstract
BACKGROUND & AIMS The availability of non-tumorigenic and tumorigenic liver progenitor cell (LPC) lines affords a method to screen putative anti-liver cancer agents to identify those that are selectively effective. To prove this principle we tested thalidomide and a range of its derivatives and compared them to lenalidomide and sorafenib, to assess their growth-inhibitory effects. METHODS Cell growth, the mitotic and apoptotic index of cell cultures were measured using the Cellavista instrument (SynenTec) using commercially available reagents. RESULTS Neither lenalidomide nor thalidomide (100 μM) affected tumorigenic LPCs but killed their non-tumorigenic counterparts. Sorafenib arrested growth in both cell types. All but two derivatives of thalidomide were ineffective; of the two effective derivatives, one (thalidomide C1) specifically affected the tumorigenic cell line (10 μM). Mitotic and apoptotic analyses revealed that thalidomide C1 induced apoptotic cell death and not mitotic arrest. CONCLUSIONS This study shows that screens incorporating non-tumorigenic and tumorigenic liver cell lines are a sound approach to identify agents that are effective and selective. A high throughput instrument such as the Cellavista affords robust and reproducible objective measurements with a large number of replicates that are reliable. These experiments show that neither lenalidomide nor thalidomide are potentially useful for anti-liver cancer therapy as they kill non-tumorigenic liver cells and not their tumorigenic counterparts. Sorafenib in contrast, is highly effective, but not selective. One tested thalidomide derivative has potential as an anti-tumor drug since it induced growth arrest; and importantly, it selectively induced apoptotic cell death only in tumorigenic liver progenitor cells.
Collapse
Affiliation(s)
- Ken Woo
- The Centre for Medical Research, The Perkins Institute of Medical Research, Nedlands, WA 6009, Australia
| | - Scott G Stewart
- School of Chemistry and Biochemistry, The University of Western Australia, Crawley, WA 6009, Australia
| | - Geraldine S Kong
- School of Chemistry and Biochemistry, The University of Western Australia, Crawley, WA 6009, Australia
| | - Megan L Finch-Edmondson
- School of Chemistry and Biochemistry, The University of Western Australia, Crawley, WA 6009, Australia
| | - Benjamin J Dwyer
- School of Chemistry and Biochemistry, The University of Western Australia, Crawley, WA 6009, Australia; The Centre for Medical Research, The Perkins Institute of Medical Research, Nedlands, WA 6009, Australia
| | - Sing Y Yeung
- School of Chemistry and Biochemistry, The University of Western Australia, Crawley, WA 6009, Australia
| | - Lawrence J Abraham
- School of Chemistry and Biochemistry, The University of Western Australia, Crawley, WA 6009, Australia
| | - Sven S Kampmann
- School of Chemistry and Biochemistry, The University of Western Australia, Crawley, WA 6009, Australia
| | - Luke A Diepeveen
- School of Chemistry and Biochemistry, The University of Western Australia, Crawley, WA 6009, Australia; The Centre for Medical Research, The Perkins Institute of Medical Research, Nedlands, WA 6009, Australia
| | - Adam M Passman
- School of Chemistry and Biochemistry, The University of Western Australia, Crawley, WA 6009, Australia
| | - Caryn L Elsegood
- School of Chemistry and Biochemistry, The University of Western Australia, Crawley, WA 6009, Australia; School of Biomedical Sciences and Curtin Health Innovation Research Institute, Curtin University, Bentley, WA, Australia
| | - Janina E E Tirnitz-Parker
- School of Biomedical Sciences and Curtin Health Innovation Research Institute, Curtin University, Bentley, WA, Australia; School of Medicine and Pharmacology, University of Western Australia, Fremantle, WA 6959, Australia
| | - Bernard A Callus
- School of Chemistry and Biochemistry, The University of Western Australia, Crawley, WA 6009, Australia; School of Health Sciences, The University of Notre Dame Australia, WA 6959, Australia
| | - John K Olynyk
- Department of Gastroenterology & Hepatology, Fiona Stanley Hospital, Bull Creek, WA, Australia; School of Biomedical Sciences and Curtin Health Innovation Research Institute, Curtin University, Bentley, WA, Australia; School of Veterinary Sciences, Murdoch University, Murdoch, WA, Australia
| | - George C T Yeoh
- School of Chemistry and Biochemistry, The University of Western Australia, Crawley, WA 6009, Australia; The Centre for Medical Research, The Perkins Institute of Medical Research, Nedlands, WA 6009, Australia.
| |
Collapse
|
15
|
Oliveira JM, Rêgo JL, de Lima Santana N, Braz M, Jamieson SE, Vieira TS, Magalhães TL, Machado PRL, Blackwell JM, Castellucci LC. The -308 bp TNF gene polymorphism influences tumor necrosis factor expression in leprosy patients in Bahia State, Brazil. INFECTION GENETICS AND EVOLUTION 2016; 39:147-154. [PMID: 26829382 DOI: 10.1016/j.meegid.2016.01.026] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/10/2015] [Revised: 01/27/2016] [Accepted: 01/28/2016] [Indexed: 02/04/2023]
Abstract
Leprosy or Hansen's disease is a debilitating chronic granulomatous disease caused by Mycobacterium leprae, with high incidence and prevalence in Brazil. The -308 bp G/A single nucleotide polymorphism (SNP rs1800629) in the tumor necrosis factor (TNF) gene promoter is a proposed risk factor for leprosy. In Brazil, Northern India, Egypt and Nepal, the common G allele was associated with leprosy. In Eastern India, Thailand and Malawi the minor A allele was the risk factor. Allele A was previously associated with high TNF. We genotyped rs1800629 in 326 leprosy cases from Bahia State, Brazil, including 72 paucibacillary (PB) and 47 multibacillary (MB) without reactions, and 69 reversal reaction (RR) and 78 erythema nodosum leprosum (ENL) with reactions. Logistic regression was used to compare patient groups with 331 healthy controls. Relative TNF mRNA was determined in peripheral blood leukocytes by QRTPCR, and serum TNF levels measured by ELISA. We found that TNF mRNA expression was higher (P=0.03) in leprosy patients compared to endemic controls, but did not differ significantly between clinical subgroups. Carriage of the minor A allele was associated (P=0.003) with low TNF mRNA across leprosy patients. Nevertheless, we found no evidence for either allele at this SNP as a risk factor for leprosy per se (OR=1.12, 95% CI 0.79-1.60, P=0.52), PB (OR=0.99, 95% CI 0.54-1.81, P=0.97), MB (OR=0.86, 95% CI 0.40-1.83, P=0.70), RR (OR=1.37, 95% CI 0.79-2.38, P=0.27) or ENL (OR=0.76, 95% CI 0.40-1.45, P=0.42) when compared to endemic controls. Further studies are required to determine whether the influence of the minor A allele on TNF mRNA levels determines response to treatment, particularly in the context of ENL reaction treatment with anti-TNF therapies and RR reactions where treatment with prednisolone is known to reduce TNF levels. Our findings contribute to understanding TNF as an important determinant of leprosy immunopathology in Brazil.
Collapse
Affiliation(s)
- Joyce Moura Oliveira
- National Institute of Science and Technology in Tropical Diseases, Brazil and Federal University of Bahia, Salvador, Brazil; Program of Post-graduation in Health Sciences, Federal University of Bahia, Salvador, Brazil.
| | - Jamile Leão Rêgo
- National Institute of Science and Technology in Tropical Diseases, Brazil and Federal University of Bahia, Salvador, Brazil; Program of Post-graduation in Health Sciences, Federal University of Bahia, Salvador, Brazil.
| | - Nadja de Lima Santana
- National Institute of Science and Technology in Tropical Diseases, Brazil and Federal University of Bahia, Salvador, Brazil; Program of Post-graduation in Health Sciences, Federal University of Bahia, Salvador, Brazil.
| | - Marcos Braz
- National Institute of Science and Technology in Tropical Diseases, Brazil and Federal University of Bahia, Salvador, Brazil; Program of Post-graduation in Health Sciences, Federal University of Bahia, Salvador, Brazil.
| | - Sarra E Jamieson
- Telethon Kids Institute, The University of Western Australia, Subiaco, Western Australia, Australia.
| | - Thaillamar Silva Vieira
- National Institute of Science and Technology in Tropical Diseases, Brazil and Federal University of Bahia, Salvador, Brazil.
| | - Thaís Lamêgo Magalhães
- National Institute of Science and Technology in Tropical Diseases, Brazil and Federal University of Bahia, Salvador, Brazil.
| | - Paulo Roberto Lima Machado
- National Institute of Science and Technology in Tropical Diseases, Brazil and Federal University of Bahia, Salvador, Brazil; Program of Post-graduation in Health Sciences, Federal University of Bahia, Salvador, Brazil.
| | - Jenefer M Blackwell
- Telethon Kids Institute, The University of Western Australia, Subiaco, Western Australia, Australia.
| | - Léa C Castellucci
- National Institute of Science and Technology in Tropical Diseases, Brazil and Federal University of Bahia, Salvador, Brazil; Program of Post-graduation in Health Sciences, Federal University of Bahia, Salvador, Brazil.
| |
Collapse
|
16
|
Kampmann SS, Skelton BW, Yeoh GC, Abraham LJ, Lengkeek NA, Stubbs KA, Heath CH, Stewart SG. The synthesis and fluorescence profile of novel thalidomide analogues. Tetrahedron 2015. [DOI: 10.1016/j.tet.2015.08.036] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
17
|
Godin AM, Araújo DP, César IC, Menezes RR, Brito AMS, Melo ISF, Coura GME, Bastos LFS, Almeida MO, Byrro RMD, Matsui TC, Batista CRA, Pianetti GA, de Fátima Â, Machado RR, Coelho MM. Activities of 2-phthalimidethyl nitrate and 2-phthalimidethanol in the models of nociceptive response and edema induced by formaldehyde in mice and preliminary investigation of the underlying mechanisms. Eur J Pharmacol 2015; 756:59-66. [PMID: 25794846 DOI: 10.1016/j.ejphar.2015.02.052] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2014] [Revised: 02/03/2015] [Accepted: 02/22/2015] [Indexed: 01/23/2023]
Abstract
The activities of 2-phthalimidethyl nitrate (PTD-NO) and 2-phthalimidethanol (PTD-OH) were recently demonstrated in models of pain and inflammation. We expanded our investigation by evaluating their activities in models of nociceptive and inflammatory pain and inflammatory edema, the preliminary pharmacokinetic parameter for PTD-NO and the role of opioid and cannabinoid pathways in the activity of analogs. Per os (p.o.) administration of PTD-NO or PTD-OH, 1h before intraplantar injection of formaldehyde, inhibited both phases of the nociceptive response (500 and 750 mg/kg) and paw edema (125, 250, 500 and 750 mg/kg). After p.o. administration of PTD-NO, peak plasma concentrations of PTD-NO and PTD-OH were found 0.92 and 1.13 h, respectively. The plasma concentrations of PTD-NO were higher than those of PTD-OH. Intraperitoneal (i.p.) administration of CB1 (AM251) or CB2 (AM630) cannabinoid receptor antagonists (4 or 8 mg/kg, -30 min) or opioid antagonist naltrexone (5 or 10mg/kg, -30 min) did not affect the antinociceptive activities of the analogs. AM251 (8 mg/kg, i.p., -30 min) attenuated the antiedematogenic activity of both analogs, while naltrexone (10mg/kg, i.p., -30 min) only attenuated the antiedematogenic activity of PTD-NO. The antiedematogenic activities of both analogs were not affected by the CB2 cannabinoid antagonist AM630 (4 or 8 mg/kg, i.p., -30 min). Concluding, we expanded the knowledge on the activities of PTD-NO and PTD-OH by showing that these phthalimide analogs also exhibit marked activity in models of nociceptive and inflammatory pain and inflammatory edema. Opioid and cannabinoid mechanisms partially mediate the anti-inflammatory, but not the antinociceptive activity.
Collapse
Affiliation(s)
- Adriana M Godin
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP, 31270-901 Belo Horizonte, Minas Gerais, Brazil
| | - Débora P Araújo
- Departamento de Química, Instituto de Ciências Exatas Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP, 31270-901 Belo Horizonte, Minas Gerais, Brazil
| | - Isabela C César
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP, 31270-901 Belo Horizonte, Minas Gerais, Brazil
| | - Raquel R Menezes
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP, 31270-901 Belo Horizonte, Minas Gerais, Brazil
| | - Ana Mercy S Brito
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP, 31270-901 Belo Horizonte, Minas Gerais, Brazil
| | - Ivo S F Melo
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP, 31270-901 Belo Horizonte, Minas Gerais, Brazil
| | - Giovanna M E Coura
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP, 31270-901 Belo Horizonte, Minas Gerais, Brazil
| | - Leandro F S Bastos
- Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP, 31270-901 Belo Horizonte, Minas Gerais, Brazil
| | - Mariana O Almeida
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP, 31270-901 Belo Horizonte, Minas Gerais, Brazil
| | - Ricardo M D Byrro
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP, 31270-901 Belo Horizonte, Minas Gerais, Brazil
| | - Tamires C Matsui
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP, 31270-901 Belo Horizonte, Minas Gerais, Brazil
| | - Carla R A Batista
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP, 31270-901 Belo Horizonte, Minas Gerais, Brazil
| | - Gerson A Pianetti
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP, 31270-901 Belo Horizonte, Minas Gerais, Brazil
| | - Ângelo de Fátima
- Departamento de Química, Instituto de Ciências Exatas Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP, 31270-901 Belo Horizonte, Minas Gerais, Brazil
| | - Renes R Machado
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP, 31270-901 Belo Horizonte, Minas Gerais, Brazil
| | - Márcio M Coelho
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP, 31270-901 Belo Horizonte, Minas Gerais, Brazil.
| |
Collapse
|
18
|
Buccini M, Punch KA, Kaskow B, Flematti GR, Skelton BW, Abraham LJ, Piggott MJ. Ethynylbenzenoid metabolites of Antrodia camphorata: synthesis and inhibition of TNF expression. Org Biomol Chem 2014; 12:1100-13. [PMID: 24385001 DOI: 10.1039/c3ob42333f] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
An improved synthesis of the anti-inflammatory natural product antrocamphin A (2), involving a key Castro-Stephens reaction, is presented, along with the first total synthesis of its congener antrocamphin B (3). Approaches towards the more complex co-metabolite antrodioxolanone (4) were unsuccessful, but a samarium diiodide-mediated pinacol coupling of antrocamphin B did provide the chiral epimers (51). Antrocamphin A (2) inhibits Tumour Necrosis Factor (TNF) reporter gene expression, but its development as an anti-inflammatory agent may be limited by cytotoxicity.
Collapse
Affiliation(s)
- Marco Buccini
- School of Chemistry and Biochemistry, The University of Western Australia, Perth, WA, Australia.
| | | | | | | | | | | | | |
Collapse
|
19
|
Godin AM, Araújo DP, Menezes RR, Brito AMS, Melo ISF, Coura GME, Soares DG, Bastos LFS, Amaral FA, Ribeiro LS, Boff D, Santos JRA, Santos DA, Teixeira MM, de Fátima Â, Machado RR, Coelho MM. Activities of 2-phthalimidethanol and 2-phthalimidethyl nitrate, phthalimide analogs devoid of the glutarimide moiety, in experimental models of inflammatory pain and edema. Pharmacol Biochem Behav 2014; 122:291-8. [PMID: 24780502 DOI: 10.1016/j.pbb.2014.04.008] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/31/2014] [Revised: 04/08/2014] [Accepted: 04/18/2014] [Indexed: 12/17/2022]
Abstract
The reintroduction of thalidomide in the pharmacotherapy greatly stimulated the interest in the synthesis and pharmacological evaluation of phthalimide analogs with new and improved activities and also greater safety. In the present study, we evaluated the activities of two phthalimide analogs devoid of the glutarimide ring, namely 2-phthalimidethanol (PTD-OH) and 2-phthalimidethyl nitrate (PTD-NO), in experimental models of inflammatory pain and edema in male C57BL/6J mice. Intraplantar (i.pl.) injection of carrageenan (300 μg) induced mechanical allodynia and this response was inhibited by previous per os (p.o.) administration of PTD-OH and PTD-NO (750 mg/kg) and also by thalidomide (500 or 750 mg/kg). The edema induced by carrageenan was also inhibited by previous p.o. administration of PTD-OH (500 and 750 mg/kg) and PTD-NO (125, 250, 500 or 750 mg/kg), but not by thalidomide. Carrageenan increased tumor necrosis factor (TNF)-α and CXCL1 concentrations and also the number of neutrophils in the paw tissue. Previous p.o. administration of PTD-NO (500 mg/kg) reduced all the parameters, while PTD-OH (500 mg/kg) reduced only the accumulation of neutrophils. Thalidomide, on the other hand, was devoid of effect on these biochemical parameters. Plasma concentrations of nitrite were increased after p.o. administration of the phthalimide analog coupled to a NO donor, PTD-NO (500 mg/kg), but not after administration of PTD-OH or thalidomide. In conclusion, our results show that small molecules, structurally much simpler than thalidomide or many of its analogs under investigation, exhibit similar activities in experimental models of pain and inflammation. Finally, as there is evidence that the glutarimide moiety contributes to the teratogenic effect of many thalidomide analogs, our results indicate that phthalimide analogs devoid of this functional group could represent a new class of analgesic and anti-inflammatory candidates with potential greater safety.
Collapse
Affiliation(s)
- Adriana M Godin
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP 31270-901, Belo Horizonte, MG, Brazil
| | - Débora P Araújo
- Departamento de Química, Instituto de Ciências Exatas, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP 31270-901, Belo Horizonte, MG, Brazil
| | - Raquel R Menezes
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP 31270-901, Belo Horizonte, MG, Brazil
| | - Ana Mercy S Brito
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP 31270-901, Belo Horizonte, MG, Brazil
| | - Ivo S F Melo
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP 31270-901, Belo Horizonte, MG, Brazil
| | - Giovanna M E Coura
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP 31270-901, Belo Horizonte, MG, Brazil
| | - Darly G Soares
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP 31270-901, Belo Horizonte, MG, Brazil
| | - Leandro F S Bastos
- Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP 31270-901, Belo Horizonte, MG, Brazil
| | - Flávio A Amaral
- Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP 31270-901, Belo Horizonte, MG, Brazil
| | - Lucas S Ribeiro
- Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP 31270-901, Belo Horizonte, MG, Brazil
| | - Daiane Boff
- Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP 31270-901, Belo Horizonte, MG, Brazil
| | - Julliana R A Santos
- Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP 31270-901, Belo Horizonte, MG, Brazil
| | - Daniel A Santos
- Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP 31270-901, Belo Horizonte, MG, Brazil
| | - Mauro M Teixeira
- Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP 31270-901, Belo Horizonte, MG, Brazil
| | - Ângelo de Fátima
- Departamento de Química, Instituto de Ciências Exatas, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP 31270-901, Belo Horizonte, MG, Brazil
| | - Renes R Machado
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP 31270-901, Belo Horizonte, MG, Brazil
| | - Márcio M Coelho
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP 31270-901, Belo Horizonte, MG, Brazil.
| |
Collapse
|
20
|
Coêlho LCD, Cardoso MVDO, Moreira DRM, Gomes PATDM, Cavalcanti SMT, Oliveira AR, Filho GBDO, Siqueira LRPD, Barbosa MDO, Borba EFDO, Silva TGD, Kaskow B, Karimi M, Abraham LJ, Leite ACL. Novel phthalimide derivatives with TNF-α and IL-1β expression inhibitory and apoptotic inducing properties. MEDCHEMCOMM 2014. [DOI: 10.1039/c4md00070f] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
24 compounds were synthesized and their immunomodulation of TNF-α and IL-1β was evaluated.
Collapse
Affiliation(s)
- Lucas Cunha Duarte Coêlho
- Departamento de Ciências Farmacêuticas
- Centro de Ciências da Saúde
- Universidade Federal de Pernambuco
- Recife, Brazil
| | | | | | | | | | - Arsenio Rodrigues Oliveira
- Departamento de Ciências Farmacêuticas
- Centro de Ciências da Saúde
- Universidade Federal de Pernambuco
- Recife, Brazil
| | | | | | - Miria de Oliveira Barbosa
- Departamento de Ciências Farmacêuticas
- Centro de Ciências da Saúde
- Universidade Federal de Pernambuco
- Recife, Brazil
| | | | | | - Belinda Kaskow
- The School of Chemistry & Biochemistry
- The University of Western Australia
- Crawley, Australia
| | - Mahdad Karimi
- The School of Chemistry & Biochemistry
- The University of Western Australia
- Crawley, Australia
| | - Lawrence J. Abraham
- School of Pathology & Laboratory Medicine
- The University of Western Australia
- Crawley, Australia
| | - Ana Cristina Lima Leite
- Departamento de Ciências Farmacêuticas
- Centro de Ciências da Saúde
- Universidade Federal de Pernambuco
- Recife, Brazil
| |
Collapse
|
21
|
Glutamic acid and its derivatives: candidates for rational design of anticancer drugs. Future Med Chem 2013; 5:961-78. [PMID: 23682571 DOI: 10.4155/fmc.13.62] [Citation(s) in RCA: 70] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Throughout the history of human civilizations, cancer has been a major health problem. Its treatment has been interesting but challenging to scientists. Glutamic acid and its derivative glutamine are known to play interesting roles in cancer genesis, hence, it was realized that structurally variant glutamic acid derivatives may be designed and developed and, might be having antagonistic effects on cancer. The present article describes the state-of-art of glutamic acid and its derivatives as anticancer agents. Attempts have been made to explore the effectivity of drug-delivery systems based on glutamic acid for the delivery of anticancer drugs. Moreover, efforts have also been made to discuss the mechanism of action of glutamic acid derivatives as anticancer agents, clinical applications of glutamic acid derivatives, as well as recent developments and future perspectives of glutamic acid drug development have also been discussed.
Collapse
|
22
|
Affiliation(s)
- Rafael Chinchilla
- Departamento de Química Orgánica, Facultad de Ciencias and Instituto de Síntesis Orgánica (ISO), Universidad de Alicante, Apartado 99, 03080 Alicante, Spain.
| | | |
Collapse
|
23
|
Yeung SY, Kampmann S, Stubbs KA, Skelton BW, Kaskow BJ, Abraham LJ, Stewart SG. Novel thalidomide analogues with potent NFκB and TNF expression inhibition. MEDCHEMCOMM 2011. [DOI: 10.1039/c1md00184a] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
24
|
Stewart SG, Braun CJ, Polomska ME, Karimi M, Abraham LJ, Stubbs KA. Efforts toward elucidating Thalidomide’s molecular target: an expedient synthesis of the first Thalidomide biotin analogue. Org Biomol Chem 2010; 8:4059-62. [DOI: 10.1039/c0ob00060d] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|